JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Erratum Notice
  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Erratum
  • Reprints and Permissions

Erratum Notice

Important: There has been an erratum issued for this article. Read More ...

Summary

This method describes the purification by flow cytometry of MEP and MKp from mice femurs, tibias, and pelvic bones.

Abstract

Bone marrow megakaryocytes are large polyploid cells that ensure the production of blood platelets. They arise from hematopoietic stem cells through megakaryopoiesis. The final stages of this process are complex and classically involve the bipotent Megakaryocyte-Erythrocyte Progenitors (MEP) and the unipotent Megakaryocyte Progenitors (MKp). These populations precede the formation of bona fide megakaryocytes and, as such, their isolation and characterization could allow for the robust and unbiased analysis of megakaryocyte formation. This protocol presents in detail the procedure to collect hematopoietic cells from mouse bone marrow, the enrichment of hematopoietic progenitors through magnetic depletion and finally a cell sorting strategy that yield highly purified MEP and MKp populations. First, bone marrow cells are collected from the femur, the tibia, and also the iliac crest, a bone that contains a high number of hematopoietic progenitors. The use of iliac crest bones drastically increases the total cell number obtained per mouse and thus contributes to a more ethical use of animals. A magnetic lineage depletion was optimized using 450 nm magnetic beads allowing a very efficient cell sorting by flow cytometry. Finally, the protocol presents the labeling and gating strategy for the sorting of the two highly purified megakaryocyte progenitor populations: MEP (Lin-Sca-1-c-Kit+CD16/32-CD150+CD9dim) and MKp (Lin- Sca-1-c-Kit+CD16/32-CD150+CD9bright). This technique is easy to implement and provides enough cellular material to perform i) molecular characterization for a deeper knowledge of their identity and biology, ii) in vitro differentiation assays, that will provide a better understanding of the mechanisms of maturation of megakaryocytes, or iii) in vitro models of interaction with their microenvironment.

Introduction

Blood platelets are produced by megakaryocytes. These large polyploid cells are located in the bone marrow and as for all blood cells they are derived from Hematopoietic Stem Cells (HSC)1. The classical pathway of production of megakaryocytes in the bone marrow originates from HSC and involves the generation of different progenitors that progressively restrict their differentiation potential2. The first progenitor signing the commitment to the megakaryocytic lineage is the Megakaryocyte-Erythrocyte Progenitor (MEP), a bipotent progenitor capable of producing both erythroid cells and megakaryocytes3,4,5. The MEP then produces a unipotent progenitor/precursor (MKp) that will differentiate into a mature megakaryocyte capable of producing platelets. The mechanisms involved in the generation of these progenitors, as well as their differentiation and maturation into megakaryocytes are complex and only partially understood. In addition, the heterogeneity of the MEP population in terms of differentiation potential and the intrinsic commitment level of these cells are still unclear. To decipher these processes, it is essential to obtain (or have access to) purified populations of MEP and MKp for fine molecular and single cell analyses.

Several studies have demonstrated particular combinations of cell surface markers for the identification of progenitors committed to the megakaryocytic lineage in the mouse6,7,8. From these a method was devised allowing the purification of MEP and MKp from mice. This method was optimized to obtain cells in adequate number and quality for a large number of assays. With ethical considerations in mind, and in order to minimize the number of animals involved in the experiments, we elicited to harvest the bone marrow from the femur and tibia, and also from the iliac crest. This bone contains a high frequency and number of hematopoietic progenitors and is most of the time damaged during long bone harvesting. Presented here is a detailed method for the reliable collection of this bone.

The second criteria of optimization is to produce highly purified cell populations. Fluorescent Activated Cell Sorting (FACS) is a method of choice in order to obtain purified populations of cells of interest. However, low yields are reached when the cell population of interest is very rare. Enrichment procedures are thus necessary. In this protocol, a negative selection procedure was opted using magnetic beads.

Protocol

Protocols involving animals were performed in accordance with the CREMEAS Committee on the Ethics of Animal Experiments of the University of Strasbourg (Comité Régional d'Ethique en Matière d'Expérimentation Animale Strasbourg. Permit Number: E67-482-10).

1. Mouse bone collection

  1. Sacrifice the animal in compliance with the institutional guidelines.
    NOTE: The data presented in this manuscript were obtained from C57Bl/6 mice of 8 to 12 weeks old. The number of cells obtained, and the frequency of cited populations may vary with age and mouse strain.
  2. Spray the body with 70% ethanol.
  3. Using scissors, make a 0.5-1 cm incision of the skin perpendicular to the spine and tear the skin around the whole body. Pull down the skin from the lower body and remove the skin.
  4. Place the animal on the dissection pad, face down. Locate the pelvic bones by sliding your fingers along the exposed spine from the top to the bottom. To locate the iliac crest, identify the small bump in the lumbar region near the hindlimbs (the anterosuperior region of the pelvic bone). Figure 1A,B presents a schematic representation of the mouse anatomy.

figure-protocol-1373
Figure 1: Mouse anatomy. (A) Mouse X-Ray showing the hindlimb bones. Note the space between the pelvic bone and the spine (yellow arrow), where the scissors must be inserted to properly separate the hindlimbs from the body of the mouse (yellow dotted line). (B) Schematic representation of the bone marrow-rich bones of interest. The pelvic bones are depicted in red, the femurs in purple, and the tibias in green. (C) Schematic representation of the mouse pelvic bone. The ilium corresponds to the marrow-rich part of the pelvic bone and is highlighted in red. Please click here to view a larger version of this figure.

  1. Place the scissors parallel to the spine against the vertebrae and close to the iliac crest bump. Proceed to cut the muscles along the side of the spine above the pelvic bone by sliding the scissors along the vertebrae all the way down to the tail.
    NOTE: This first section of muscles can also be performed using a scalpel blade.
  2. Place the scissors parallel to the spine and proceed to cut between the vertebrae and the iliac crest, as indicated by the yellow dotted line on Figure 1A. Make sure to remain as close to the vertebrae as possible. Cut the remaining muscles to detach the limb from the body.
    NOTE: There should be little to no resistance.
  3. Repeat on the other side to detach the second limb.
  4. Transfer the limbs on a clean surface and discard the rest of the body in compliance with the institutional guidelines.
  5. Expose the pelvic, femoral, and tibial bones by removing as much surrounding tissue as possible with the forceps and the scalpels.
  6. Proceed to carefully dislocate the femoral head from the pelvic bone by holding the distal end of the femur with the forceps while gently slicing the muscles around the articulation with the scalpels. Wiggle the bones to facilitate the dislocation.
  7. Scrape off the remaining muscle from the pelvic bone and cut with a scalpel in the middle of the cavity that did hold the femur head. The ilium is kept as it is rich in hematopoietic progenitors while the triangular very thin side of the bone is discarded, as shown in Figure 1C.
  8. Remove the residual tissues around the ilium with the scalpel and place the cleaned bone in sterile PBS supplemented with 2% Newborn Calf Serum (PBS-2%NBCS).
  9. Using scissors, cut off the foot from the leg at the ankle.
  10. Hold the lower part of the tibia with the forceps and scrape the muscle up toward the knee. Discard the fibulae and cut across the tibial plateau with the scalpel. Place the tibia in sterile PBS-2%NBCS.
  11. Remove the residual tissues around the femur with scalpels.
  12. Hold the upper side of the femur with forceps; place the scalpel blade at the base of the kneecap. Apply a force toward the kneecap parallel to the femur until the detachment of the kneecap. Place the femur in sterile PBS-2%NBCS. Removal of the kneecap provides a clean access for inserting the needle for marrow flushing.

2. Magnetic depletion of lineage positive cells

  1. In a laminar flow cabinet, transfer the bones in a sterile Petri dish filled with sterile PBS-2%NBCS.
  2. With a scalpel cut off the head of the femurs.
  3. Fill a 1 mL syringe with sterile PBS-2%NBCS and attach a 21 G needle to the outlet.
  4. Fill a 5 mL polypropylene tube with 2 mL of sterile PBS-2%NBCS.
  5. Hold the femur with the forceps; gently insert the needle in the groove left after the kneecap removal. Apply rotation to the needle while inserting to avoid plugging of the needle. Ensure that the needle is completely inserted into the bone up to the bevel.
  6. Transfer the bone with the needle into the tube containing 2 mL of PBS-2%NBCS. Dispense and aspirate the PBS-2%NBCS from the syringe until the bone is clear.
  7. Remove the needle from the femur and insert it in the hole at opposite side where the femur head was. Dispense and aspirate the buffer again and discard the bone.
  8. For the iliac crest and tibia, hold the bone with the forceps; gently insert the needle in the open side. Apply rotation to the needle while inserting to avoid plugging of the needle. Ensure that the needle is completely inserted into the bone up to the bevel. Transfer the bone with the needle into the tube containing 2 mL of PBS-2%NBCS. Dispense and aspirate the PBS-2%NBCS from the syringe until the bone is clear. Discard the bones.
    NOTE: Bones from up to three mice can be flushed into the same tube. Pool the cell suspensions.
  9. Pass the pooled cell suspension through a 40 µm cell strainer cap placed onto a sterile 5 mL polystyrene tube.
  10. Proceed to count the cells.
    NOTE: Cell count can be performed with any hemocytometer, using Trypan Blue for viability assessment, or with any automated cell counter. One mouse typically yields 105 ± 7 x 106 cells.
  11. Take aside 100 µL of the cell suspension as Total Bone Marrow, add 500 µL of PBS-2%NBCS and save it on ice for the staining procedure.
  12. Pellet the filtered suspension by centrifugation at 400 x g for 5 min at 4 °C and discard the supernatant.
    NOTE: Red blood cells can be lysed by resuspending the pellet in freshly prepared Lysis Solution (1/10th in dH2O). Incubate for 5 min until the suspension becomes clear and bright red and add 10 volumes of sterile PBS. Proceed to wash the cells in PBS-2%NBCS by centrifugation at 400 x g for 5 mins at 4 °C. Be careful when removing the supernatant as the cell pellet is very loose. Perform a second wash with PBS-2%NBCS by centrifugation at 400 x g for 5 min at 4 °C and proceed to step 2.13.
  13. Resuspend the cell pellet in freshly prepared primary antibody cocktail with a ratio of 100 µL per 1 x 107 cells. Incubate on ice for 30-45 min.
AntibodyDilution
Gr-1-biotin1:500
B220-biotin1:500
Mac-1-biotin1:500
CD3-biotin1:500
CD4-biotin1:500
CD5-biotin1:500
CD8-biotin1:500
TER119-biotin1:1000
CD127-biotin1:500

Table 1.

  1. Take aside 10 µL of the cell suspension into a sterile 5 mL polystyrene tube labeled Lin-Pos Fraction. Add 90 µL of PBS-2%NBCS and save it on ice for the staining procedure.
  2. Proceed to wash the cells twice with sterile PBS-2%NBCS by centrifugation at 400 x g for 5 min at 4 °C. Make sure to do the last wash in a sterile 5 mL polypropylene tube.
  3. During the washing steps, prepare the beads for the magnetic depletion.
    1. Resuspend the beads in the vial by thoroughly vortexing for 30 s.
    2. Transfer a volume of beads corresponding to two beads per target cell into a 5 mL polypropylene tube.
    3. Wash the beads twice with PBS-2%NBCS by placing the tube on the magnet and removing the washing buffer using a sterile glass Pasteur pipette.
    4. Resuspend the beads in 500 µL of sterile PBS-2NBCS%.
  4. Resuspend the pellet of labeled cells in 250 µL of beads and mix gently for 5 min on ice. Add 2 mL of sterile PBS-2%NBCS and mix gently. Do not shake the tube.
  5. Place the tube onto the magnet for 2 min.
  6. Proceed to collect the non-magnetic fraction with a sterile glass Pasteur pipette and add it onto the remaining 250 µL of magnetic beads. Seal the tube with parafilm.
  7. Place the tube on a tube roller for 20 min at 4 °C.
  8. Add 2 mL of sterile PBS-2%NBCS and mix gently. Do not shake the tube.
  9. Place the tube in the magnet for 2 min.
  10. Proceed to collect the non-magnetic fraction into a sterile 5 mL polypropylene tube labeled Lin-Neg Fraction with a sterile glass Pasteur pipette.
  11. Pellet the cells by centrifugation at 400 x g for 5 min at 4 °C and remove the supernatant.
  12. Resuspend the non-magnetic cells in 500 µL of sterile PBS-2%NBCS.
  13. Proceed to count the cells.
    ​NOTE: One mouse typically yields 3.9 ± 1.1 x 106 cells. Typical lineage staining pre- and post- depletion are presented in Figure 2B.

3. Cell sorting of megakaryocyte progenitors by flow cytometry

  1. Take the tubes labeled Total Bone Marrow, Lin-Pos Fraction, and Lin-Neg Fraction.
  2. Proceed to split the content of the tube Total Bone Marrow equally into six sterile 5 mL polystyrene tubes. Label the tubes with the numbers 1-6.
  3. Proceed to label the tube Lin-Pos Fraction with the number 7.
  4. Proceed to split the content of the tube Lin-Neg Fraction as follows.
    1. Transfer 50 µL into a sterile 5 mL polystyrene tube containing 250 µL of sterile PBS-2%NBCS. Then, split its content equally into 3 sterile 5 mL polystyrene tubes. Label these tubes with the numbers 8-10.
    2. The remaining 450 µL of Lin-Neg Fraction cell suspension corresponds to the tube with the number 11.
  5. Add the antibodies to the tubes as described in Table 2.
TubeLabelAntibody cocktail
Total Bone Marrow
1Unstained control
2Single stained controlCD45-FITC (1/200)
3Single stained controlCD45-PE (1/200)
4Single stained controlTER119-APC (1/200)
5Single stained controlCD45-PECy7 (1/200)
6Single stained controlCD45-APC-Cy7 biotin (1/200)
Lin-Pos Fraction
7Single stained controlSingle stained control. Streptavidin-APC-Cy7 (1/500)
Lin-Neg Fraction
8FMO FITC control c-kit-APC (1/200) + Sca-1-PE (1/200) +
CD16/32-PE (1/200) + CD150-PECy7 (1/200) + Streptavidin-APC-Cy7 (1/500)
9FMO PE controlCD9-FITC (1/200) + c-kit-APC (1/200) + CD150-PECy7 (1/200) + Streptavidin-APC-Cy7 (1/500)
10FMO PECy7 controlCD9-FITC (1/200) + c-kit-APC (1/200) + Sca-1-PE (1/200) +
CD16/32-PE (1/200) + Streptavidin-APC-Cy7 (1/500)
11Positive tube for sortingCD9-FITC (1/200) + c-kit-APC (1/200) + Sca-1-PE (1/200) +
CD16/32-PE (1/200) + CD150-PECy7 (1/200) + Streptavidin-APC-Cy7 (1/500)

Table 2.

  1. Incubate on ice for 30-45 min in the dark.
  2. Wash the cells with sterile PBS-2%NBCS by centrifugation at 400 x g for 5 min at 4 °C.
  3. Resuspend the cell pellets as follows.
    1. For the tubes 1 to 10, resuspend the pellet in 300 µL of sterile PBS-2%NBCS supplemented with 7AAD (2.5 µg/mL final) (PBS-7AAD).
      CAUTION: 7AAD is a DNA intercalant and must therefore be handled with appropriate PPE (gloves).
    2. For tube 11, resuspend the pellet in sterile PBS-7AAD at a maximum concentration of 5 x 106 cells per mL and a minimum volume of 1 mL.
  4. Prepare two polypropylene collection tubes labeled MEP and MKp containing 2 mL of PBS-2%NBCS.
    NOTE: Alternatively, cells can be collected into culture medium or cell lysis buffer depending on the subsequent application for the sorted cells. The use of polystyrene tubes is not recommended because of possible interference with the charged droplets containing the cells of interest.
  5. Keep all tubes on ice in the dark.
  6. Proceed to the cell sorter set-up.
    1. Use the tubes 1-7 to set-up voltage and compensation, tubes 7-10 to determine the sorting gates for the cell populations of interest and tube 11 for cell sorting.
  7. The first steps of the gating strategy aim to exclude doublets and dead cells from the analysis, as described in Figure 3. Identify single viable cells and display SSC-vs Lin-APC-Cy7 dot plot to confirm the efficiency of the lineage depletion. From the Lin- cells a gate is set to select cells positive for c-kit and negative or dim for Sca-1 and CD16/32. A CD9 vs CD150 expression dot plot for the selected cells allows the identification of four populations.
    NOTE: MEP and MKp cells are both positive for CD150. Three levels of expression for CD9 can be defined (neg, dim, and high). MKp express high level of CD9 and MEP express CD9 at an intermediate fluorescence intensity level. MEP population corresponds to Lin- c-Kit+ Sca-1-CD16/32-/dim CD150+ CD9dim and MKp population corresponds to Lin- c-Kit+ Sca-1-CD16/32-/dim CD150+ CD9bright. The discrimination between CD9 high and CD9 dim populations for the CD150 positive cells is set based on the maximum level of CD9 expression in the CD150 negative population. One mouse typically yields 5.3 ± 0.6 x 103 MKp and 27.2 ± 2.4 x 103 MEP.

Results

Phenotypic analysis of the cells identified as MEP and MKp were performed by flow cytometry. Cells were labeled with fluorescence conjugated antibodies to CD41a and CD42c, classical markers of the megakaryocytic and platelet lineages. Both markers were expressed by the cells of the MKp population while these markers are not yet detected at the surface of the cells of the MEP population (Figure 4Ai,4Aii). Polyploidy is a hallmark of megakaryocytes. The DNA content of the sort...

Discussion

The method described in this paper allows for the extraction and purification of mouse MEP and MKp. An important parameter in the optimization of the protocol was to obtain sufficient number of cells that would be compatible with most molecular- and cellular-based assays. The general practice of mouse bone collection for hematopoietic cell extraction usually consists in harvesting both the femurs and tibias of each mouse. The pelvic bone, another source of hematopoietic material, is thus often overlooked. The reasons for...

Disclosures

The authors declare no competing financial interests.

Acknowledgements

The authors wish to thank Monique Freund, Catherine Ziessel and Ketty for technical assistance. This work was supported by ARMESA (Association de Recherche et Développement en Médecine et Santé Publique), and by Grant ANR-17-CE14-0001-01 to Henri.de la.Salle.

Materials

NameCompanyCatalog NumberComments
21-gauge needlesBD Microlance301155
7AADSigma-AldrichA9400
Antibody Gr-1-biotineBioscience13-5931-85Magnetic depletion
Antibody B220-biotineBioscience13-0452-85Magnetic depletion
Antibody Mac-1-biotineBioscience13-0112-85Magnetic depletion
Antibody CD3e-biotineBioscience13-0031-85Magnetic depletion
Antibody CD4-biotineBioscience13-9766-82Magnetic depletion
Antibody CD5-biotineBioscience13-0051-85Magnetic depletion
Antibody CD8a-biotineBioscience13-0081-85Magnetic depletion
Antibody TER119-biotineBioscience13-5921-85Magnetic depletion
Antibody CD127-biotineBioscience13-1271-85Magnetic depletion
Antibody CD45-FITCeBioscience11-0451-85Cell sorting
Antibody CD45-PEeBioscience12-0451-83Cell sorting
Antibody TER119-APCeBioscience17-5921-83Cell sorting
Antibody CD45-PECy7eBioscience25-0451-82Cell sorting
Antibody CD45-biotineBioscience13-0451-85Cell sorting
Antibody CD9-FITCeBioscience11-0091-82Cell sorting
Antibody  c-kit-APCeBioscience17-1171-83Cell sorting
Antibody Sca-1-PEeBioscience12-5981-83Cell sorting
Antibody CD16/32-PEeBioscience12-0161-83Cell sorting
Antibody CD150-PECy7eBioscience25-1502-82Cell sorting
Culture medium StemSpan-SFEMStemcell technologies#09650
Dissection padFisher Scientific10452395
DPBSLife Technologies14190-094
EthanolvWR Chemicals83813.360
ForcepsEuronexiaP-120-AS
Glass pasteur pipetteDutscher42011
Magnet :  DynaMag-5Thermo Fisher Scientific12303D
Magnetic beads: Dynabeads Sheep Anti-Rat IgGThermo Fisher Scientific11035
MegacultStemcell technologies#04970
MethoCult SF M3436Stemcell technologies#03436
Newborn Calf SerumDutscher50750-500
Red Cell Lysis solutionBD Bioscience555899
ScalpelsFisher Scientific12308009
ScissorsEuronexiaC-165-ASB
Sterile 1 mL syringesBD Bioscience303172
Sterile 15mL tubesSarstedt62.554.502
Sterile 5mL polypropylene tubesFalcon352063
Sterile 5mL polystyrene tubesFalcon352054
Sterile tubes with 70µm cell strainer capFalcon352235
Sterile petri dishFalcon353003
Streptavidin-APC-Cy7BD Biosciences554063Cell sorting
Tube rollerBenchmark ScientificR3005

References

  1. Kaushansky, K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 111 (3), 981-986 (2008).
  2. Akashi, K., Traver, D., Miyamoto, T., Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 404 (6774), 193-197 (2000).
  3. Debili, N., et al. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood. 88 (4), 1284-1296 (1996).
  4. Forsberg, E. C., Serwold, T., Kogan, S., Weissman, I. L., Passegué, E. New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ multipotent hematopoietic progenitors. Cell. 126 (2), 415-426 (2006).
  5. Vannucchi, A. M., et al. Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. Blood. 95 (8), 2559-2568 (2000).
  6. Pronk, C. J., et al. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell. 1 (4), 428-442 (2007).
  7. Nakorn, T. N., Miyamoto, T., Weissman, I. L. Characterization of mouse clonogenic megakaryocyte progenitors. Proceedings of the National Academy of Sciences of the United States of America. 100 (1), 205-210 (2003).
  8. Ng, A. P., et al. Characterization of thrombopoietin (TPO)-responsive progenitor cells in adult mouse bone marrow with in vivo megakaryocyte and erythroid potential. Proceedings of the National Academy of Sciences of the United States of America. 109 (7), 2364-2369 (2012).
  9. Strassel, C., et al. Hirudin and heparin enable efficient megakaryocyte differentiation of mouse bone marrow progenitors. Experimental Cell Research. 318 (1), 25-32 (2012).
  10. Brouard, N., et al. A unique microenvironment in the developing liver supports the expansion of megakaryocyte progenitors. Blood Advances. 1 (21), 1854-1866 (2017).
  11. Boscher, J., Gachet, C., Lanza, F., Léon, C. Megakaryocyte culture in 3D methylcellulose-based hydrogel to improve cell maturation and study the impact of stiffness and confinement. Journal of Visualized Experiments:JOVE. , (2021).
  12. Sanjuan-Pla, A., et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature. 502 (7470), 232-236 (2013).
  13. Haas, S., et al. Inflammation-driven fast-track differentiation of HSCs into the megakaryocytic lineage. Experimental Hematology. 42 (8), 14 (2014).
  14. Shin, J. Y., Hu, W., Naramura, M., Park, C. Y. High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. The Journal of Experimental Medicine. 211 (2), 217-231 (2014).

Erratum


Formal Correction: Erratum: Isolation of Mouse Megakaryocyte Progenitors
Posted by JoVE Editors on 7/28/2021. Citeable Link.

An erratum was issued for: Isolation of Mouse Megakaryocyte Progenitors. A figure was updated.

Figure 2 was updated from:

Figure 2
Figure 2: Magnetic depletion of lineage committed (Lin) cells. (A) Schematic representation of the magnetic depletion protocol. First, unsorted bone marrow cells are labeled with the biotin-conjugated rat anti-mouse antibody cocktail. Cells are then incubated with anti-rat Ig coated magnetic beads and subsequently subjected to the magnetic depletion using a strong magnet. The magnet will retain the labeled magnetic Lin+ fraction against the tube walls, while the unlabeled non-magnetic Lin- negative fraction will be collected in a new tube. (B) Lineage committed cells can be identified using fluorescent conjugated streptavidin. Typical analysis of the lineage expression in cells prior to magnetic depletion (total bone marrow) and after magnetic depletion (Lin- Fraction) N = 21. Please click here to view a larger version of this figure.

to:

Figure 2
Figure 2: Magnetic depletion of lineage committed (Lin) cells. (A) Schematic representation of the magnetic depletion protocol. First, unsorted bone marrow cells are labeled with the biotin-conjugated rat anti-mouse antibody cocktail. Cells are then incubated with anti-rat Ig coated magnetic beads and subsequently subjected to the magnetic depletion using a strong magnet. The magnet will retain the labeled magnetic Lin+ fraction against the tube walls, while the unlabeled non-magnetic Lin- negative fraction will be collected in a new tube. (B) Lineage committed cells can be identified using fluorescent conjugated streptavidin. Typical analysis of the lineage expression in cells prior to magnetic depletion (total bone marrow) and after magnetic depletion (Lin- Fraction) N = 21. Please click here to view a larger version of this figure.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Megakaryocyte ProgenitorsIsolation ProtocolCell CultureLineage HierarchyAnimal EthicsCell SortingC57BL 6 MousePelvic Bone DissectionTissue RemovalSterile PBSNewborn Calf SerumFemur DislocationTibia Preparation

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved